Systemic Onset Juvenile Rheumatoid Arthritis (SOJRA) Children present with spiking fevers, rash, enlarged liver / spleen, lymphadenopathy, systemic inflammation,

Slides:

Advertisements

Similar presentations

COMPUTER AIDED DIAGNOSIS: CLASSIFICATION Prof. Yasser Mostafa Kadah –

Advertisements

Learning Algorithm Evaluation

Hatem Eleishi, MD Rheumatologist STILL’S DISEASE.

Lecture 22: Evaluation April 24, 2010.

Supplementary Figure 1 pH MW/1000 numberspot label Protein biomarker 11 (a,b)APO1 22GSN 33TTR 44FGB 55FGG 66APOD 77APOE 88 (a,b)ATIII 99 (a,b)A2M 1010.

History of PMR 1888 First described as senile rheumatic gout (Bruce) 1936Secondary fibrositis 1945Periarthrosis humeroscapular 1946Peri-extra-articular.

SJIA flare signature analysis 2 Discovery set (ND.SAF vs. AF.QOM.RD.KD.FI) 1 LCMS raw spectra Peak finding peak alignment feature extraction Urine peptide.

Assuming normally distributed data! Naïve Bayes Classifier.

Adult Still’s Disease Grant Paulsen AM Report May 22, 2009.

Classification and risk prediction Usman Roshan. Disease risk prediction What is the best method to predict disease risk? –We looked at the maximum likelihood.

Value of inflammatory markers Useful for diagnosis of inflammatory vs non inflammatory conditions Remember NON-SPECIFIC, increased in infection, inflammation,

Supplementary Figure 1 pH MW/1000 numberspot label Protein biomarker 11 (a,b)APO1 22GSN 33TTR 44FGB 55FGG 66APOD 77APOE 88 (a,b)ATIII 99 (a,b)A2M 1010.

Classifier training FDR analysis Predictor discovery in training set 4 Training set SJIA (12 F, 12 Q) 1 DIGE raw gel images Matched samples SJIA (10 F,

Background and Objective:Materials and Methods: Results: Conclusion: Samples were collected before Methotrexate treatment. The transcriptomes were determined.

1 Evaluating Model Performance Lantz Ch 10 Wk 5, Part 2 Right – Graphing is often used to evaluate results from different variations of an algorithm. Depending.

Exagen Diagnostics, Inc., all rights reserved Biomarker Discovery in Genomic Data with Partial Clinical Annotation Cole Harris, Noushin Ghaffari.

Sample peptides: -Class 1:1,2,3… -Class 2:1,2,3… -Class 3:1,2,3… SCX/RP-HPLC Collect 100 fractions on MALDI plates MALDI-TOF MS for each sample LC fraction.

Marc Bonin Department of Rheumatology and Clinical Immunology Charité University Hospital Charitéplatz 1 D Berlin Germany Tel: +49(0)

Generalizing Linear Discriminant Analysis. Linear Discriminant Analysis Objective -Project a feature space (a dataset n-dimensional samples) onto a smaller.

CpSc 810: Machine Learning Evaluation of Classifier.

Technological Educational Institute Of Crete Department Of Applied Informatics and Multimedia Intelligent Systems Laboratory Statistical Decision Making.

Urine peptide biomarkers in Systemic Juvenile Idiopathic Arthritis (SJIA) Xuefeng B. Ling 1, Ken Lau 1, Jane Park 2,3, Claudia Macaubas 3, Jane C. Burns.

1 Assessing Disease Activity Janice Booth Rheumatology Nurse Practitioner January 2012.

Classifier training FDR analysis Predictor discovery in training set 4 Training set SJIA (12 F, 12 Q) 1 DIGE raw gel images Matched samples SJIA (10 F,

AISTATS 2010 Active Learning Challenge: A Fast Active Learning Algorithm Based on Parzen Window Classification L.Lan, H.Shi, Z.Wang, S.Vucetic Temple.

Predictor discovery in training set 6 Training set SJIA (24 F, 14 Q) POLY (15 F, 10 Q) 1 DIGE raw gel images SJIA (13 F, 13 Q) POLY (5 F, 5 Q) Spot finding.

Predictor discovery in training set 6 Training set SJIA (24 F, 14 Q) POLY (15 F, 10 Q) 1 DIGE raw gel images SJIA (13 F, 13 Q) POLY (5 F, 5 Q) Spot finding.

Applications of Supervised Learning in Bioinformatics Yen-Jen Oyang Dept. of Computer Science and Information Engineering.

Still’s Disease Kala Dunn th.

Classifiers!!! BCH364C/391L Systems Biology / Bioinformatics – Spring 2015 Edward Marcotte, Univ of Texas at Austin.

Juvenile Idiopathic arthritis and infectious arthritis 郭三元 Division of R-I-A TSGH.

Classifier training Mann Whitney Predictor discovery in training set 4 Training set SJIA (12 F, 12 Q) POLY (13 F, 10 Q) 1 DIGE raw gel images SJIA (10.

A classification model for predicting eye disease in newly diagnosed people with type 2 diabetes Simon Lebech Cichosz, Mette Dencker Johansen, Søren.

Increased Exhaled Nitric Oxide and Risk of Loss of Control in Children Undergoing Clinical Asthma Remission D.V. Chang, J.E. Balinotti, C. Castro Simonelli,

EVALUATION OF SOLUBLE CD14 SUBTYPE (PRESEPSIN)

From: Assessment of the Accuracy of Procalcitonin to Diagnose Postoperative Infection after Cardiac Surgery Anesthes. 2007;107(2): doi: /01.anes ad.

Figure Legend: From: Fixations on low-resolution images

From: What do we perceive in a glance of a real-world scene?

Additional file 2: Figure S1

From: Combined Thoracic Ultrasound Assessment during a Successful Weaning Trial Predicts Postextubation Distress Anesthes. 2017;127(4): doi: /ALN

Albarouni, Mohammed 1, Becker, Ingrid 2, Horneff, Gerd 1

From: Objects predict fixations better than early saliency

Support Vector Machines (SVM)

Maggie Davis Hovda, MD 3/22/2010

Classification Discriminant Analysis

C. Steininger, M. Redlberger, W. Graninger, M. Kundi, T. Popow-Kraupp

A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast Cancer Gen Wang, Xiaosong.

Disease Activity Assessment Across the RA Continuum

Identifying and validating biomarkers for Alzheimer's disease

Host transcriptional profiling distinguishes patients with acute LRTI (LRTI+C+M) from those with noninfectious acute respiratory illness (no-LRTI). Host.

Volume 7, Issue 4, Pages (April 2005)

Ectopic pregnancy diagnosis and the pseudo-sac

Identifying and validating biomarkers for Alzheimer's disease

Endoscopic and Clinical Variables That Predict Sustained Remission in Children With Ulcerative Colitis Treated With Infliximab Dan Turner, Anne M. Griffiths,

Nat. Rev. Rheumatol. doi: /nrrheum

ROC Curves and Operating Points

Recurrence-Associated Long Non-coding RNA Signature for Determining the Risk of Recurrence in Patients with Colon Cancer Meng Zhou, Long Hu, Zicheng.

Nicholas Wettersten, MD, Alan S. Maisel, MD

Fig. 3 ROC curves of mCCNA1 and mVIM assayed in esophageal cytology brushings from control normal-appearing GE junctions versus BE and EAC cases. ROC curves.

Receiver operator characteristic (ROC) curve analysis of the plasma biomarker panels for differentiating ARDS (cases) from controls in patients with severe.

Diagnostic Value of C-Reactive Protein for Predicting Activity Level of Crohn’s Disease Patrick Chamouard, Zoe Richert, Nicolas Meyer, Gabriel Rahmi,

Basics of ML Rohan Suri.

A and B, ROC curves of the proteomics panel diagnosis.

Volume 85, Issue 3, Pages (March 2014)

Walter Reinisch, Jean-Frederic Colombel, William J

Cumulative probability of time to achieve first sustained DAS28 (CRP) remission by conversion to ACPA seronegative status. Cumulative probability of time.

Predicting drug sensitivity from proteomic (RPPA) data clusters.

Cox proportional-hazards model of time to first RA flare after treatment withdrawal for patients who entered the re-treatment period (n=146). Cox proportional-hazards.

Acute Phase Reactants in Patients with UPIA

Presentation transcript:

Systemic Onset Juvenile Rheumatoid Arthritis (SOJRA) Children present with spiking fevers, rash, enlarged liver / spleen, lymphadenopathy, systemic inflammation, and arthritis 50 % Remission

Predictor discovery in training set 1 sample set A (11 F, 10 Q) PAM Classifier training analysis Cross-validation Biomarker panels Study Design Gaussian LDA Class prediction in testing set 3 sample set B (10 F, 10 Q) PAM Class prediction ROC curve analysis Power analysis Sample size estimation 2 Select optimum panel Unsupervised clustering

Figure 4 Training AUC = 0.97 SJIA F Q classifier 29 feature panel Testing AUC = 0.73 Sensitivity 1- Specificity Goodness of class separation –  probability Feature# * Flare Quiescent A B

Sample set A + B n = Clinical diagnosis FQ n = Clustered as F Clustered as Q Percent Agreement with clinical diagnosis 81% 85% % Overall P = 3 X SJIA FSJIA Q 2d cluster *** * SJIA Q with impending F * SJIA F with impending Q

F F (low)QF 11/0612/0602/0704/07 Diagnosis Clinical visit date Peptide signal ESR JC Ferritin CRP N.D.

11/0612/0602/0704/07 Clinical visit date F F (low)QF Diagnosis PO pred Peptide Signal

11/0612/0602/0704/07 F F (low)QF Diagnosis Clinical visit date WBC PLT Peptide signal

11/0612/0602/0704/07 Clinical visit date F F (low)QF Diagnosis Peptide Signal MTX dose